ORGANIGRAM HOLDINGS INC (OGI.CA) Stock News
TSX:OGI - Toronto Stock Exchange - CA68620P7056 - Common Stock - Currency: CAD
OGI.CA Latest News, Press Relases and Analysis
Organigram Reports First Quarter Fiscal 2025 Results
Mentions: OGI
Organigram to Report First Quarter Fiscal 2025 Results on February 11, 2025
Mentions: OGI
Organigram Reports Fourth Quarter and Fiscal 2024 Results
Mentions: OGI
Organigram to Report Fourth Quarter and Fiscal 2024 Results on December 18, 2024
Mentions: OGI
Organigram Wants To Become Canada's Largest Cannabis Company By Market Share Via $71M Acquisition Deal
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) has announced the acquisition of 100% of Motif Labs Ltd. for CA$90 million ($64 million), comprising of CA$50 million in cash and CA$40 million in Organigram common shares, based on a 30-day trading VWAP of $2.321 on the TSX. An additional CA$10 million contingent consideration is payable in shares, conditional on achieving a share price above $3.2203 within 12 months. The deal is financed through Organigram's cash reserves.
Mentions: OGI
Organigram Acquires Motif, Becoming Canada’s Largest Cannabis Company by Market Share
Mentions: OGI
Tobacco Giant Invests $30.8M In Cannabis Company: BAT Private Placement Second Of Three Tranches
Cannabis producer Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) has closed the second of three tranches of the previously announced CA$124,559,674 ($92.3 million) follow-on strategic equity investment by BT DE Investments Inc., a wholly owned subsidiary of British American Tobacco plc, (NYSE: BTI) on Tuesday. Under the second tranche closing, the investor acquired Organigram's 4,429,740 common shares and 8,463,435 Class A preferred shares at CA$3.2203 per share, for gross proceeds of $30.8 million. The company said on Tuesday that the remaining 12,893,175 shares subscribed for are due to be issued at the per-share price in the final tranche on or around February 28, 2025.
Organigram Closes Second Tranche of Previously Announced BAT Private Placement Investment
Mentions: OGI
Organigram Reports Third Quarter Fiscal 2024 Results
Mentions: OGI
Organigram Product Development Collaboration Completes Landmark Clinical Study on Nanoemulsion Technology
Mentions: OGI
Organigram to Report Third Quarter Fiscal 2024 Results on August 13, 2024
Mentions: OGI
Organigram Announces Appointment of Craig Harris to Board of Directors
Mentions: OGI
Organigram to Bolster Auto-Flower and Rare Cannabinoid Portfolio with Partial Third Tranche Investment of US $1M into Phylos
Mentions: OGI
Organigram Invests in Sanity Group, a Leading German Cannabis Company
Mentions: OGI
Organigram Signs Three Year Supply Agreement with Avida Medical in UK
Mentions: OGI
Organigram Reports Second Quarter Fiscal 2024 Results
Mentions: OGI
Organigram to Report Second Quarter Fiscal 2024 Results on May 14, 2024
Mentions: OGI
Organigram Recognized for Executive Gender Diversity by the Globe & Mail’s Women Lead Here Report for the Fourth Consecutive Year
Mentions: OGI
Organigram’s Popular SHRED Brand Surpasses $200 Million in Yearly Retail Sales
Mentions: OGI
Organigram Successfully Closes Previously Announced Underwritten Public Offering
Mentions: OGI
Organigram Announces Pricing of Overnight Marketed Public Offering
Mentions: OGI
Organigram Announces Launch of Overnight Marketed Public Offering
Mentions: OGI
Organigram Invests in U.S. Based Open Book Extracts Representing Inaugural Jupiter Investment
Mentions: OGI
Organigram Applauds the Standing Committee on Finance’s Recommendation on Excise Duty
Mentions: OGI
Organigram Reports First Quarter Fiscal 2024 Results
Mentions: OGI
Organigram to Report First Quarter Fiscal 2024 Results on February 13, 2024
Mentions: OGI
Organigram Completes First Shipment to Germany, Extending its International Reach
Mentions: OGI
Organigram Announces the First Tranche Closing from BAT Investment
Mentions: OGI
Organigram Announces Appointment of Karina Gehring to Board of Directors
Mentions: OGI